July 11, 2017 - "Continued strong financial performance"
OCTOBER 2 2017 The lead candidate drug in the OX-MPI program has been identified as a highly selective anti-inflammatory compound. Gesynta which today acquired the assets relating to OX-MPI aims to progress the candidate drug into proof-of-concept clinical trials.
Rapport om epidemin kring opioidberoende iUSA. 2016 dog ca 60 000 amerikaner av en överdos relaterat till opioider. https://t.co/0jewvigOFX